Story perspectives
Court Ruling Threatens Drug Patents, Teva Plans Appeal
6/12/2025
38 9
1 of 1
Story summary
- A recent court ruling impacts drug-device patents, changing FDA's Orange Book listings.
- Patents must now explicitly name active ingredients, jeopardizing brand-name market protections.
- Teva intends to appeal the ruling, which could affect various pharmaceutical patents.
- Patent lawyers are required to use precise language to ensure Orange Book eligibility.
